Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Apr
23
Today In Oncology
CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma
Bispecific Antibody Shows Deep Remission in Patients With Relapsed/Refractory Follicular Lymphoma
Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases
Pretreatment MRI Prognostic Information After Radical Prostatectomy
Early-Onset ICI-Related Myocarditis Linked to Increased Mortality
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo